المؤلفون: Davide Rossi, Rahel Schwotzer, Raphael Heimgartner, Andreas J. Flammer, Georg Stussi, Bernhard Gerber, Guido Ghilardi, Erika Lerch, Christine Waibel, Harald Seeger, Clemens Caspar, Stefanie Pederiva, Thomas Fehr, Elena Bianchi, Markus G. Manz, Sofie Brouwers

المساهمون: Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Clinical Pharmacy, Experimental Pharmacology, University of Zurich, Schwotzer, Rahel

المصدر: Hematological Oncology. 37:595-600

مصطلحات موضوعية: Male, Cancer Research, 2720 Hematology, Immunoglobulin Light-chain Amyloidosis/diagnosis, Severity of Illness Index, Gastroenterology, Antineoplastic Agents, Immunological, 0302 clinical medicine, Bone Marrow, Recurrence, Immunoglobulin Light-chain Amyloidosis, 10035 Clinic for Nephrology, 1306 Cancer Research, Bortezomib, Amyloidosis, Antibodies, Monoclonal, Hematology, General Medicine, Middle Aged, Treatment Outcome, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Retreatment, 10209 Clinic for Cardiology, 2730 Oncology, Female, medicine.drug, Adult, medicine.medical_specialty, Plasma Cells, Infections/etiology, 610 Medicine & health, Infections, Antibodies, Monoclonal/administration & dosage, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Refractory, Internal medicine, medicine, AL amyloidosis, Humans, Lymphocyte Count, Adverse effect, Aged, Lenalidomide, Bone Marrow/metabolism, business.industry, Daratumumab, medicine.disease, Drug Resistance, Neoplasm, 10032 Clinic for Oncology and Hematology, Plasma Cells/pathology, Bone marrow, business, 030215 immunology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afce2e4f761edbd1d13b6d39b85360dfTest
https://doi.org/10.1002/hon.2677Test

المؤلفون: Mazhar Ajaz, Laurent Mortier, Inge Marie Svane, Ivan Marquez-Rodas, Thomas Eigentler, Jennifer Lord-Bessen, Paolo A. Ascierto, Elena Grigoryeva, Dirk Schadendorf, Caroline Robert, Linda Rollin, Jacopo Pigozzo, Nicolas Meyer, Michael Smylie, Rene Gonzalez, Alexander M. Menzies, Piotr Rutkowski, Céleste Lebbé, Abdel Saci

المصدر: Journal of Clinical Oncology
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998Test

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Skin Neoplasms, Time Factors, Medizin, Gastroenterology, law.invention, 0302 clinical medicine, Antineoplastic Agents, Immunological, Randomized controlled trial, law, Skin Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Melanoma/drug therapy, Ipilimumab/administration & dosage, Melanoma, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Progression-Free Survival, 3. Good health, Nivolumab/administration & dosage, Nivolumab, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Female, Rapid Communication, medicine.drug, Adult, medicine.medical_specialty, Ipilimumab, Drug Administration Schedule, 03 medical and health sciences, Young Adult, Antineoplastic Agents, Immunological/administration & dosage, Double-Blind Method, Internal medicine, medicine, Humans, Dosing, Progression-free survival, Adverse effect, Aged, Neoplasm Staging, business.industry, Clinical trial, 030104 developmental biology, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7100d36b125a105d0de169d7144e1e3eTest
https://pubmed.ncbi.nlm.nih.gov/30811280Test

المؤلفون: Magdalena Jadwiga Utsch, Anna Krilova, Özlem Türeci, Martin Schuler, Karl Dhaene, Markus Jerling, Christoph Rohde, Stefan Bauer, Tobias Dechow, Ugur Sahin, Heike Richly, Christoph Huber

المساهمون: Supporting clinical sciences, Experimental Pathology

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, medicine.medical_specialty, Time Factors, Esophageal Neoplasms, Maximum Tolerated Dose, medicine.medical_treatment, Medizin, Gastroenterology, Antibodies, Monoclonal/administration & dosage, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Pharmacokinetics, Antineoplastic Agents, Immunological/administration & dosage, Stomach Neoplasms, Internal medicine, Germany, medicine, Humans, Drug Dosage Calculations, Adverse effect, Infusions, Intravenous, Aged, business.industry, Cancer, Antibodies, Monoclonal, Esophagogastric Junction/drug effects, Immunotherapy, Middle Aged, medicine.disease, Latvia, ddc, 030104 developmental biology, Treatment Outcome, Oncology, Tolerability, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Toxicity, Disease Progression, Female, Stomach Neoplasms/drug therapy, Esophagogastric Junction, Esophageal Neoplasms/drug therapy, business, Progressive disease

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdb9949f013111d7e7dd98d889459c98Test
https://doi.org/10.1016/j.ejca.2018.05.007Test